**Comparing Treatment Approaches for Knee Ligament Laxity and Torn Ligaments: Interventional Orthobiologics Versus Surgical Options – A Regenexx Perspective** Knee...

**Gene Therapy Trial Evaluates Efficacy of Cancer-Targeting Virus in Treating Brain Tumors** In the ever-evolving landscape of cancer treatment, gene...

### 2024 PRP Randomized Controlled Trial Infographic 2.0 by Regenexx: A Comprehensive Overview In the ever-evolving field of regenerative medicine,...

**Comparative Study on the Effectiveness of Stem Cells and Microvesicles in Treating Chronic Renal Injury in Rats: Histological and Biochemical...

**Comparative Analysis of Stem Cells and Microvesicles in Treating Chronic Renal Injury in Rats: A Histological and Biochemical Study –...

**Comparative Study on the Effectiveness of Stem Cells and Microvesicles in Treating Chronic Renal Injury in Rats: A Histological and...

**Jonathan Thomas Appointed as New President and CEO of CIRM** In a significant development for the field of regenerative medicine,...

# $53 Million Allocated for Clinical and Translational Research Funding: A Leap Forward in Medical Innovation In a significant move...

**The Role of FOXM1-Dependent Histone Linker H1B in Human Epidermal Stem Cells: Implications for Cell Death and Disease** The human...

**The Role of FOXM1-Dependent Histone Linker H1B in Human Epidermal Stem Cells: Insights from Cell Death & Disease** Human epidermal...

**Correction Notice: Influence of Thyroid Hormone Receptor β on Cancer Stem Cell Activity – Oncogene** In the ever-evolving field of...

**Nevada Approves Controversial Unproven Therapies, Joining Other States in Challenging FDA Regulations on Biologics** In a move that has sparked...

**QC Kinetix Shifts Focus from Upselling to Cost Reduction – Regenexx Reports** In the ever-evolving landscape of regenerative medicine, QC...

# Effective Approaches for Modeling Aging and Age-Related Diseases Aging is an inevitable biological process that affects all living organisms....

**Infographic on the 2024 PRP Randomized Controlled Trial by Regenexx: A Comprehensive Overview** In the ever-evolving field of regenerative medicine,...

# Semaphorin 3C (Sema3C) Modulates Stromal Microenvironment to Facilitate Hepatocellular Carcinoma Advancement – Insights from Signal Transduction and Targeted Therapy...

**Semaphorin 3C (Sema3C) Modulates Stromal Microenvironment to Facilitate Hepatocellular Carcinoma Progression – Insights from Signal Transduction and Targeted Therapy** Hepatocellular...

**Lung Institute Stem Cell Clinic Ordered to Pay $9 Million in Class Action Lawsuit Settlement** In a landmark decision, the...

**Innovative Stem Cell Therapy for Treating Cystic Fibrosis-Related Sinusitis** Cystic fibrosis (CF) is a genetic disorder that primarily affects the...

**Innovative Stem Cell Therapy for Treating Sinusitis in Cystic Fibrosis Patients** Cystic fibrosis (CF) is a genetic disorder that primarily...

**Cytosolic N-terminal Formyl-Methionine Deformylation Promotes Cancer Stem Cell Characteristics and Tumor Progression** Cancer remains one of the most formidable challenges...

**Deformylation of Cytosolic N-terminal Formyl-Methionine Promotes Cancer Stem Cell Characteristics and Tumor Progression – Scientific Reports** Cancer remains one of...

**miR-124-3p Reduces EGR1 Expression to Mitigate Ischemia-Hypoxia Reperfusion Injury in Human iPS Cell-Derived Cardiomyocytes – Scientific Reports** Ischemia-hypoxia reperfusion injury...

**miR-124-3p Suppresses Ischemia-Hypoxia Reperfusion Injury in Human iPS Cell-Derived Cardiomyocytes by Downregulating EGR1 – Scientific Reports** Ischemia-hypoxia reperfusion (IHR) injury...

**Lack of Response from FDA Commissioner Robert Califf on Stem Cell Clinics Raises Concerns** In recent years, the burgeoning field...

**Uniting the Community at the 2nd Annual ALSP Conference** In an era where legal innovation is rapidly transforming the landscape...

# Uniting the Community: Highlights from the 2nd Annual ALSP Conference The 2nd Annual Alternative Legal Service Providers (ALSP) Conference,...

**First-of-Their-Kind 3D Brain Models Incorporate Cells from Multiple Donors: A Leap Forward in Neuroscience** In a groundbreaking advancement for neuroscience,...

**Chimeric Brain Organoids Reflect the Spectrum of Human Genetic Diversity** In recent years, the field of neuroscience has witnessed groundbreaking...

### Utilizing Elaeagnus angustifolia L. Extract for Green Synthesis of Nanohydroxyapatite as a Metronidazole Nanocarrier in In Vitro Pulpitis Model...

“Improvement of Endothelial Function and Reduction of Portal Vein Injury with miRNA-25-3p-Expressing Mesenchymal Stem Cells – Scientific Reports”

# Improvement of Endothelial Function and Reduction of Portal Vein Injury with miRNA-25-3p-Expressing Mesenchymal Stem Cells – Scientific Reports

## Introduction

The field of regenerative medicine has seen significant advancements in recent years, particularly in the use of mesenchymal stem cells (MSCs) for therapeutic purposes. One promising area of research involves the use of microRNAs (miRNAs) to enhance the efficacy of MSCs. Among these, miRNA-25-3p has garnered attention for its potential to improve endothelial function and reduce portal vein injury. This article delves into the latest scientific reports on the subject, highlighting the mechanisms, benefits, and future prospects of miRNA-25-3p-expressing MSCs.

## Understanding Endothelial Function and Portal Vein Injury

### Endothelial Function

The endothelium is a thin layer of cells lining the blood vessels, playing a crucial role in vascular health. It regulates blood flow, vascular tone, and platelet activity, and serves as a barrier between the blood and the rest of the vessel wall. Dysfunction of the endothelium is a precursor to various cardiovascular diseases, including atherosclerosis, hypertension, and thrombosis.

### Portal Vein Injury

The portal vein is a major blood vessel that carries blood from the gastrointestinal tract and spleen to the liver. Injury to the portal vein can result from conditions such as cirrhosis, thrombosis, or surgical interventions. Such injuries can lead to severe complications, including portal hypertension, variceal bleeding, and liver failure.

## The Role of miRNA-25-3p in Vascular Health

MicroRNAs are small non-coding RNAs that regulate gene expression post-transcriptionally. miRNA-25-3p has been identified as a key regulator in various biological processes, including cell proliferation, apoptosis, and angiogenesis. Recent studies have shown that miRNA-25-3p can modulate endothelial function and protect against vascular injuries.

### Mechanisms of Action

1. **Anti-inflammatory Effects**: miRNA-25-3p has been shown to downregulate pro-inflammatory cytokines and upregulate anti-inflammatory mediators, thereby reducing inflammation in endothelial cells.

2. **Promotion of Angiogenesis**: By targeting specific genes involved in angiogenesis, miRNA-25-3p promotes the formation of new blood vessels, which is crucial for tissue repair and regeneration.

3. **Inhibition of Apoptosis**: miRNA-25-3p can inhibit apoptosis (programmed cell death) in endothelial cells by regulating apoptotic pathways, thus enhancing cell survival.

## Mesenchymal Stem Cells (MSCs) as Therapeutic Agents

MSCs are multipotent stem cells capable of differentiating into various cell types, including osteoblasts, chondrocytes, and adipocytes. They possess immunomodulatory properties and can secrete a range of bioactive molecules that promote tissue repair and regeneration.

### Advantages of MSCs

1. **Immunomodulation**: MSCs can modulate immune responses, making them suitable for treating inflammatory conditions.

2. **Paracrine Effects**: MSCs secrete growth factors, cytokines, and extracellular vesicles that aid in tissue repair.

3. **Homing Ability**: MSCs can migrate to sites of injury, where they exert their therapeutic effects.

## Combining miRNA-25-3p with MSCs

The combination of miRNA-25-3p with MSCs represents a novel therapeutic strategy to enhance endothelial function and reduce portal vein injury. By genetically modifying MSCs to overexpress miRNA-25-3p, researchers aim to harness the synergistic effects of both components.

### Scientific Findings

Recent scientific reports have demonstrated the efficacy of miRNA-25-3p-expressing MSCs in preclinical models:

1. **Enhanced Endothelial Function**: Studies have shown that miRNA-25-3p-expressing MSCs significantly improve endothelial function by reducing oxidative stress and enhancing nitric oxide production.

2. **Reduction in Portal Vein Injury**: In animal models of portal vein injury, treatment with miRNA-25-3p-expressing MSCs resulted in reduced inflammation, decreased fibrosis, and improved vascular integrity.

3. **Improved Liver Function**: The therapeutic effects extended to improved liver function, as evidenced by reduced liver enzyme levels and enhanced liver regeneration.

## Future Prospects

The promising results from preclinical studies pave the way for clinical trials to evaluate the safety and efficacy of miRNA-25-3p-expressing MSCs in humans. Future research should focus on optimizing delivery methods, dosing regimens, and long-term outcomes.

### Potential Applications

1. **Cardiovascular Diseases**: Given their ability to improve endothelial function, miRNA-25-3p-expressing MSC